Literature DB >> 3558203

Artificial pulmonary surfactant inhibited by proteins.

T Fuchimukai, T Fujiwara, A Takahashi, G Enhorning.   

Abstract

With a pulsating bubble surfactometer we assessed the ability of various agents, fibrinogen, human serum, albumin, and a 55,000-dalton serum protein, to interfere with the surface activity of Surfactant TA. From a highest final protein concentration of 4 mg/ml the potential inhibitors were diluted down to 0.125 mg/ml in six steps, and each concentration was evaluated together with two final phospholipid concentrations, 6.25 and 1.25 mg/ml, of the surfactant preparation. The strongest inhibiting action was exerted by fibrinogen, followed by human serum and the 55,000-dalton serum protein; the weakest inhibitor was albumin. Bilirubin, when added in an amount of 1.73 mg/100 ml dissolved in human serum, significantly (P less than 0.001) augmented the inhibition over that exerted by human serum alone. Adsorption rate, as reflected in the mean value of surface tension 2 and 10 s after creation of a bubble, not pulsating, was seriously affected by each of the protein-containing inhibitors in concentrations exceeding 1 mg/ml. Surface tension was raised significantly when the pulsating bubble was at maximal and minimal size. The effect was dose dependent. At maximal size it showed no tendency to disappear during the 10-min recording, but at minimal bubble size the inhibition gradually diminished. We conclude that proteins present in the airways may seriously interfere with the activity of Surfactant TA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3558203     DOI: 10.1152/jappl.1987.62.2.429

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  30 in total

1.  A concentration-dependent mechanism by which serum albumin inactivates replacement lung surfactants.

Authors:  H E Warriner; J Ding; A J Waring; J A Zasadzinski
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

2.  Exogenous surfactant treatment for the adult respiratory distress syndrome? A historical perspective.

Authors:  N S Morton
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

Review 3.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

4.  Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits.

Authors:  M Gupta; J M Hernandez-Juviel; A J Waring; F J Walther
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 5.  Surfactant therapy for meconium aspiration syndrome: current status.

Authors:  Peter A Dargaville; John F Mills
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Therapeutic use of surfactant components in allergic asthma.

Authors:  Veit J Erpenbeck; Norbert Krug; Jens M Hohlfeld
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

Review 7.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

8.  In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function.

Authors:  B Lachmann; E P Eijking; K L So; D Gommers
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

9.  Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial).

Authors:  H L Halliday; W O Tarnow-Mordi; J D Corcoran; C C Patterson
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

10.  Effects of surfactant on lung injury induced by hyperoxia and mechanical ventilation in rabbits.

Authors:  J Ikegaki; K Mikawa; H Obara
Journal:  J Anesth       Date:  1993-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.